View in EDS

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

Saved in:
Bibliographic Details
Title: Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Authors: Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Kersting S; Department of Hematology, HAGA Hospital, The Hague, The Netherlands., van Norden Y; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Dobber JA; Laboratory Special Hematology and., Mellink CH; Laboratory of Cytogenetics, Academic Medical Center, Amsterdam, The Netherlands., Evers LM; Laboratory Special Hematology and., Croon-de Boer F; Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands., Schreurs J; Internal Medicine, Martini Hospital, Groningen, The Netherlands., van der Spek E; Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands., Visser H; Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands., Idink C; Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands., Wittebol S; Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands., Hoogendoorn M; Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Tonino SH; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Mobasher M; Genentech, Inc, South San Francisco, CA; and., Levin MD; Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Corporate Authors: HOVON CLL study group.
Source: Blood advances [Blood Adv] 2018 Dec 26; Vol. 2 (24), pp. 3566-3571.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30552161
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kersting+S%22">Kersting S</searchLink>; Department of Hematology, HAGA Hospital, The Hague, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Norden+Y%22">van Norden Y</searchLink>; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dubois+J%22">Dubois J</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dobber+JA%22">Dobber JA</searchLink>; Laboratory Special Hematology and.<br /><searchLink fieldCode="AU" term="%22Mellink+CH%22">Mellink CH</searchLink>; Laboratory of Cytogenetics, Academic Medical Center, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Evers+LM%22">Evers LM</searchLink>; Laboratory Special Hematology and.<br /><searchLink fieldCode="AU" term="%22Croon-de+Boer+F%22">Croon-de Boer F</searchLink>; Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Schreurs+J%22">Schreurs J</searchLink>; Internal Medicine, Martini Hospital, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Spek+E%22">van der Spek E</searchLink>; Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Visser+H%22">Visser H</searchLink>; Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Idink+C%22">Idink C</searchLink>; Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Wittebol+S%22">Wittebol S</searchLink>; Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hoogendoorn+M%22">Hoogendoorn M</searchLink>; Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Tonino+SH%22">Tonino SH</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mobasher+M%22">Mobasher M</searchLink>; Genentech, Inc, South San Francisco, CA; and.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22HOVON+CLL+study+group%2E%22">HOVON CLL study group.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2018 Dec 26; Vol. 2 (24), pp. 3566-3571.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30552161
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2018019422
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3566
    Titles:
      – TitleFull: Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kater AP
      – PersonEntity:
          Name:
            NameFull: Kersting S
      – PersonEntity:
          Name:
            NameFull: van Norden Y
      – PersonEntity:
          Name:
            NameFull: Dubois J
      – PersonEntity:
          Name:
            NameFull: Dobber JA
      – PersonEntity:
          Name:
            NameFull: Mellink CH
      – PersonEntity:
          Name:
            NameFull: Evers LM
      – PersonEntity:
          Name:
            NameFull: Croon-de Boer F
      – PersonEntity:
          Name:
            NameFull: Schreurs J
      – PersonEntity:
          Name:
            NameFull: van der Spek E
      – PersonEntity:
          Name:
            NameFull: Visser H
      – PersonEntity:
          Name:
            NameFull: Idink C
      – PersonEntity:
          Name:
            NameFull: Wittebol S
      – PersonEntity:
          Name:
            NameFull: Hoogendoorn M
      – PersonEntity:
          Name:
            NameFull: Tonino SH
      – PersonEntity:
          Name:
            NameFull: Mobasher M
      – PersonEntity:
          Name:
            NameFull: Levin MD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 12
              Text: 2018 Dec 26
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 2
            – Type: issue
              Value: 24
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1